Search results for " trials"

showing 10 items of 932 documents

Factors associated with maximal walking speed among older community-living adults.

2011

Background and aims: The relative contribution of different domains on walking speed is largely unknown. This study investigated the central factors associated with maximal walking speed among older people. Methods: Cross-sectional analyses of baseline data from the SCAMOB study (ISRCTN 07330512) involving 605 community-living ambulatory adults aged 75–81 years. Maximal walking speed, leg extensor power, standing balance and body mass index were measured at the research center. Physical activity, smoking, use of alcohol, chronic diseases and depressive symptoms were self-reported by standard questionnaires. Results: The mean maximal walking speed was 1.4 m/s (range 0.3–2.9). In linear regre…

AdultMaleAgingmedicine.medical_specialtyPosturePhysical activityWalkingModels BiologicalBody Mass IndexPhysical medicine and rehabilitationCommunity livingLinear regressionPostural BalanceMedicineHumansGaitFinlandAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industrymedicine.diseaseObesityPreferred walking speedCross-Sectional StudiesAmbulatoryPhysical therapyFemaleHousing for the ElderlyGeriatrics and GerontologybusinessBody mass indexAging clinical and experimental research
researchProduct

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

2005

BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m2 as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow wit…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidMaximum Tolerated DoseGemtuzumab ozogamicinmedicine.medical_treatmentCD33Sialic Acid Binding Ig-like Lectin 3Antigens Differentiation MyelomonocyticHematopoietic stem cell transplantationNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleClinical Trials Phase II as TopicAntigens CDRecurrenceInternal medicinemedicineHumansSingle-Blind MethodSurvival rateAgedAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseGemtuzumabSurgerySurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureAminoglycosidesTreatment OutcomeOncologyEvaluation Studies as TopicFemalebusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

Sublingual administration of captopril in patients with acute myocardial ischemia.

1991

Summary: To investigate the anti-ischemic capability of the angiotensin-converting enzyme inhibitor captopril, 10 patients with acute myocardial ischemia (angina pectoris >1 h, ST-segment depression ±0.1 mV, no rise in creatine phosphokinase) received 25 mg captopril sublingually after being treated with an intravenous infusion of nitroglycerin (3 mg/h) and heparin (1200 IU/h) for 1 hour. A control group of 10 patients received placebo instead of captopril. Results showed a decrease of the initial ST-segment depression from 0.25±0.04 to 0.2±0.03 mV (p>0.01) with nitroglycerin for the captopril group and from 0.26±0.05 to 0.21±0.05 mV (p>0.01) for the control group. An additional decrease to…

AdultMaleCaptoprilAdministration SublingualCoronary DiseasePlaceboSublingual administrationAngina PectorisAnginaElectrocardiographyNitroglycerinHeart ratemedicineHumanscardiovascular diseasesMyocardial infarctionCreatine KinaseClinical Trials as Topicbiologybusiness.industryHemodynamicsCaptoprilGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureAnesthesiaAcute DiseaseVascular resistancebiology.proteinCreatine kinaseDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical cardiology
researchProduct

Temsirolimus for the treatment of mantle cell lymphoma.

2010

Although recent progress has been made in the treatment of mantle cell lymphoma (MCL) the majority of patients experience relapse and ultimately die of their disease. The translocation t(11;14) is a prerequisite for the diagnosis of MCL and results in overexpression of cyclin D1. Its protein translation is controlled by mTOR, a key element of the PI3K/Akt pathway, and mTOR constitutes an attractive therapeutic target. Temsirolimus, a specific inhibitor of mTOR, has been evaluated in two Phase II trials in patients with relapsed MCL, and promising response rates up to 40% were found. Subsequently, a randomized Phase III trial was initiated, in which superiority in remission induction and pro…

AdultMaleCombination therapyChromosomal translocationAntineoplastic AgentsLymphoma Mantle-CellPharmacologyDisease-Free SurvivalDrug Administration ScheduleCyclin D1hemic and lymphatic diseasesmedicineSecondary PreventionHumansCyclin D1PI3K/AKT/mTOR pathwayAgedAged 80 and overSirolimusClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesRemission InductionIntracellular Signaling Peptides and ProteinsHematologyMiddle Agedmedicine.diseaseTemsirolimusNon-Hodgkin's lymphomaRegimenCancer researchMantle cell lymphomaFemalebusinessmedicine.drugExpert review of hematology
researchProduct

Treatment of Ulcerative Colitis with Olsalazine and Sulphasalazine: Efficacy and Side-Effects

1988

The effects of olsalazine were studied mainly in patients with ulcerative colitis who were intolerant to sulphasalazine, and for relapse prevention. A crossover design with sulphasalazine, 3 g/day, and olsalazine, 1.5 g/day, was applied to compare the side-effects of each drug and to evaluate their therapeutic efficacy. A total of 41 patients with mild or moderately severe left-sided colitis or proctitis were assigned to a randomized treatment schedule. Olsalazine and sulphasalazine were similar in their therapeutic efficacy. Twelve patients complained of adverse effects while on sulphasalazine and 4 patients during olsalazine treatment (p less than 0.05). It is concluded that olsalazine is…

AdultMaleDrugmedicine.medical_specialtymedia_common.quotation_subjectRelapse preventionGastroenterologyRandom AllocationDouble-Blind MethodInternal medicinemedicineHumansProctitisColitisAdverse effectProctitismedia_commonOlsalazineClinical Trials as Topicbusiness.industryGastroenterologymedicine.diseaseUlcerative colitisCrossover studySulfasalazineAminosalicylic AcidsColitis UlcerativeFemalebusinessmedicine.drugScandinavian Journal of Gastroenterology
researchProduct

Health benefits of different sport disciplines for adults: systematic review of observational and intervention studies with meta-analysis

2015

The aim was to assess the quality and strength of evidence for the health benefits of specific sport disciplines. Electronic search yielded 2194 records and the selection resulted in 69 eligible studies (47 cross-sectional, 9 cohort, 13 intervention studies). 105 comparisons between participation and non-participation groups in 26 different sport disciplines were reported. Moderately strong evidence showed that both running and football improve aerobic fitness and cardiovascular function at rest, and football reduces adiposity. Conditional evidence showed that running benefits metabolic fitness, adiposity and postural balance, and football improves metabolic fitness, muscular performance, p…

AdultMaleGerontologymedicine.medical_specialtyHealth Statusmedia_common.quotation_subjectHealth BehaviorPhysical Therapy Sports Therapy and RehabilitationHealth PromotionFootballHealth benefitsRunningRisk FactorsSoccerPostural BalanceHumansMedicineAerobic exerciseOrthopedics and Sports MedicineQuality (business)Prospective StudiesSwimmingmedia_commonClinical Trials as Topicbusiness.industryGeneral MedicineObservational Studies as TopicPhysical FitnessMeta-analysisAthletic InjuriesCohortPhysical therapyFemaleObservational studybusinessSportsBritish Journal of Sports Medicine
researchProduct

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODI…

2021

Abstract Immune checkpoint inhibitors have failed in treating metastatic colorectal cancer (mCRC) patients except those with dMMR/MSI tumors. However, until very recently we had only non-comparative promising data in this population with anti-programmed cell death 1/ programmed cell death ligand 1 (PD1/PD-L1) antibodies alone or combined with anti- cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies. This comparative phase II trial (NCT 03186326), conducted in more than 100 centers in France, will include dMMR/MSI mCRC patients with progression after a first-line treatment with chemotherapy ± targeted therapies, to evaluate efficacy and safety of the anti-PDL1 Avelumab versus a s…

AdultMaleOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationECOG Performance StatusAntibodies Monoclonal HumanizedAvelumab03 medical and health sciencesAntineoplastic Agents ImmunologicalClinical Trials Phase II as Topic0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopiceducationRandomized Controlled Trials as TopicChemotherapyeducation.field_of_studyHepatologybusiness.industryGastroenterologyMicrosatellite instabilityImmunotherapymedicine.diseaseProgression-Free SurvivalRegimen030220 oncology & carcinogenesisFemaleMicrosatellite Instability030211 gastroenterology & hepatologyFranceColorectal Neoplasmsbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials

2005

Summary Background Chemotherapy is the standard treatment for advanced non-small-cell lung cancer, and myelosuppression is a common side-effect. We aimed to assess whether haematological toxic effects could be a biological measure of drug activity and a marker of efficacy. Methods We analysed data for 1265 patients who received chemotherapy (vinorelbine, gemcitabine, gemcitabine and vinorelbine, cisplatin and vinorelbine, or cisplatin and gemcitabine) within three randomised trials. Primary landmark analyses were restricted to 436 patients who received all six planned chemotherapy cycles and who were alive 180 days after randomisation. Neutropenia was categorised on the basis of worst WHO g…

AdultMaleOncologymedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentAntineoplastic AgentsNeutropenia.VinorelbineSeverity of Illness IndexCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansLung cancerSurvival rateAgedProportional Hazards ModelsRandomized Controlled Trials as TopicAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryStandard treatmentHazard ratioMiddle Agedrandomized clinical trialmedicine.diseaseGemcitabineSurgerySurvival Ratelandmark analysisnon-small-cell lung cancerItalyOncologychemotherapy-induced neutropeniaFemaleDrug MonitoringbusinessBiomarkersmedicine.drug
researchProduct

Quantitative sensory testing: a comprehensive protocol for clinical trials.

2004

We have compiled a comprehensive QST protocol as part of the German Research Network on Neuropathic Pain (DFNS) using well established tests for nearly all aspects of somatosensation. This protocol encompasses thermal as well as mechanical testing procedures. Our rationale was to test for patterns of sensory loss (small and large nerve fiber functions) or gain (hyperalgesia, allodynia, hyperpathia), and to assess both cutaneous and deep pain sensitivity. The practicality of the QST protocol was tested in 18 healthy subjects, 21-58 years, half of them female. All subjects were tested bilaterally over face, hand and foot. We determined thermal detection and pain thresholds including a test fo…

AdultMalePain Thresholdmedicine.medical_specialtyAudiologyClinical ProtocolsThreshold of painmedicineHumansPain MeasurementClinical Trials as TopicReproducibility of ResultsSensory lossHypoesthesiaMiddle AgedAnesthesiology and Pain MedicineAllodyniaHyperalgesiaResearch DesignAnesthesiaNeuropathic painHyperalgesiaHyperpathiaBody regionFemalemedicine.symptomPsychologyEuropean journal of pain (London, England)
researchProduct

Strategy for Long-Term Surveillance at the German Childhood Cancer Registry - an Update

2011

Background The objective of this paper is to provide information about the quality (e.g. completeness, response) of long-term surveillance in German paediatric oncology and haematology based on the structures implemented by the German Childhood Cancer Registry (GCCR). Methods The GCCR contacts parents or patients to collect and update information on a minimal set of follow-up health status data (e.g. late relapses, subsequent neoplasms, current address) and exchanges this information regularly with the appropriate clinical trials. Results Between 2006 and 2010, GCCR approached a total of about 20,000 patients (contact at the age of 16 years, inquiry concerning the health status) in the cont…

AdultMalePediatricsmedicine.medical_specialtyAdolescentDatabases FactualLymphomaCross-sectional studyHealth StatusMEDLINECentral Nervous System NeoplasmsCohort StudiesGermanYoung AdultCause of DeathGermanyNeoplasmsHumansMedicineRegistriesSurvivorsYoung adultChildClinical Trials as TopicChildhood Cancer RegistryLeukemiabusiness.industryMiddle AgedLong-Term CareSurvival Analysislanguage.human_languageClinical trialLong-term careCross-Sectional StudiesChild PreschoolPopulation SurveillanceFamily medicinePediatrics Perinatology and Child HealthQuality of LifelanguageFemalebusinessCohort studyKlinische Pädiatrie
researchProduct